Hepatocyte growth factor therapy - Kringle Pharma/ChronTech Pharma

Drug Profile

Hepatocyte growth factor therapy - Kringle Pharma/ChronTech Pharma

Alternative Names: ChronSeal

Latest Information Update: 18 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kringle Pharma; Tripep
  • Developer ChronTech Pharma; Kringle Pharma
  • Class Antifibrotics; Growth factors; Neuropsychotherapeutics
  • Mechanism of Action Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Leg ulcer

Most Recent Events

  • 18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Norway (Topical)
  • 18 Jun 2014 No development reported - Phase-I/II for Leg ulcer in Sweden (Topical)
  • 21 Apr 2011 Clinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top